Tetsuya Mori

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Hodgkin Lymphoma

Chemotherapy Induced

Top Venues

European journal of haematology

International journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Tetsuya Mori, Tomoo Osumi, Akiko Kada, Kentaro Ohki, Yuhki Koga, Reiji Fukano, Naoto Fujita, Tetsuo Mitsui, Takeshi Mori, Akiko M Saito, Atsuko Nakazawa, Ryoji Kobayashi, Masahiro Sekimizu
Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial. European journal of haematology (2023)
Tetsuya Mori, Tomoo Osumi, Akiko Kada, Kentaro Ohki, Yuhki Koga, Reiji Fukano, Naoto Fujita, Tetsuo Mitsui, Takeshi Mori, Akiko M Saito, Atsuko Nakazawa, Ryoji Kobayashi, Masahiro Sekimizu
Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial. European journal of haematology 112 (4) (2023)
Tetsuya Mori, Tomoo Osumi, Akiko Kada, Kentaro Ohki, Yuhki Koga, Reiji Fukano, Naoto Fujita, Tetsuo Mitsui, Takeshi Mori, Akiko M Saito, Atsuko Nakazawa, Ryoji Kobayashi, Masahiro Sekimizu
Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial. European journal of haematology 112 (4) (2023)
Yuhki Koga, Masahiro Sekimizu, Akihiro Iguchi, Akiko Kada, Akiko M Saito, Ryuta Asada, Tetsuya Mori, Keizo Horibe
Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma. International journal of hematology 111 (5) (2020)